Table 2.

Detailed clinical information of the patients included in the training and validation datasets.

Category	GEO (n = 279)		TCGA (n = 447)
OS (years ± SD)	2.88 ± 1.72		3.58 ± 3.27
Age (years ± SD)	50.38 ± 10.70		57.65 ± 12.87
Death	59 (21.15%)		66 (14.77%)
Alive	220 (78.85%)		381 (85.23%)
TNM-T0/T1	21 (7.53%)		117 (26.17%)
TNM-T2	153 (54.84%)		262 (58.61%)
TNM-T3	61 (21.86%)		47 (10.51%)
TNM-T4	44 (15.77%)		21 (4.70%)
TNM-N0	79 (28.32%)		168 (37.58%)
TNM-N1	133 (47.67%)		181 (40.49%)
TNM-N2	37 (13.26%)		70 (15.66%)
TNM-N3	30 (10.75%)		28 (6.26%)
TNM-M0	–		436 (97.54%)
TNM-M1	–		11 (2.46%)
Grade-1	18 (6.45%)		–
Grade-2	109 (39.07%)		–
Grade-3	142 (50.90%)		–
Grade-4	10 (3.58%)		–
Stage-I	6 (2.15%)		67 (14.99%)
Stage-II	151 (54.12%)		246 (55.03%)
Stage-III	122 (43.73%)		122 (27.29%)
Stage-IV	–		12 (2.68%)
HER2-Positive	3 (1.08%)		66 (14.77%)
HER2-Negative	276 (98.92%)		381 (85.23%)
ESR1-Positive	156 (55.91%)		–
ESR1-Negative	123 (44.09%)		–
PR-Positive	126 (45.16%)		302 (67.56%)
PR-Negative	153 (54.84%)		145 (32.44%)
ER-Positive	158 (56.63%)		350 (78.30%)
ER-Negative	121 (43.37%)		97 (21.70%)
PAM50-Normal	23 (8.24%)		9 (2.01%)
PAM50-LumA	87 (31.18%)		217 (48.55%)
PAM50-LumB	41 (14.70%)		111 (24.83%)
PAM50-Basal	111 (39.78%)		78 (17.45%)
PAM50- Her2	17 (6.09%)		32 (7.16%)
GGI-High	185 (66.31%)		–
GGI-Low	94 (33.69%)		–
RCB-0/I	82 (29.39%)		–
RCB-II	124 (44.44%)		–
RCB-III	73 (26.16%)		–
Immunity-Low	140 (50.18%)		–
Immunity-High	139 (49.82%0		–
Chemosensitivity-Insensitive	178 (63.80%)		–
Chemosensitivity-Sensitive	101 (36.20%)		–
Riskscore-Low	231 (82.80%)		319 (71.36%)
Riskscore-High	48 (17.20%)		128 (28.64%)